Clinical Trial Reveals Promising Brain Therapeutic Drug for the Pre-Dementia Stage of Alzheimer’s Disease

Clinical Trial Reveals Promising Brain Therapeutic Drug for the Pre-Dementia Stage of Alzheimer’s Disease
Pharmaceutical company AgeneBio recently announced the publication of results of a Phase 2 clinical trial based on the company's therapeutic product AGB101 for the pre-dementia stage of Alzheimer’s disease in the journal NeuroImage: Clinical. The study entitled “Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance” was conducted by researchers at Johns Hopkins University in Baltimore and supported by the National Institutes of Health (NIH). Alzheimer’s disease is an age-related, neurodegenerative disorder where individuals initially experience memory loss and confusion that gradually leads to behavior and personality changes, a decline in cognitive abilities, and ultimately the severe loss of mental function. Alzheimer’s disease is characterized by the formation of amyloid plaques in the brain and the loss of neurons that are responsible for memory and learning. It is estimated that by age 85, one in every three individuals will have Alzheimer’s disease. Currently, 25 million people worldwide, including 5.6 million Americans, are estimated to suffer from a symptomatic, pre-dementia stage of Alzheimer’s disease called amnestic mild cognitive impairment (aMCI), which is characterized by a significant memory loss. AgeneBio has developed the therapeutic product AGB101 as a once-a-day low-dose formulation based on levetiracetam, which is a safe anti-epileptic medication that has been on the market for more than a decade. AGB101 contains a low dose of levetiracetam, approximately one-fifteenth of the dose commonly prescribed for epilepsy. It is known that overactivity in the hippocampus of aMCI patients leads to cognitive impairment and progression
Subscribe or to access all post and page content.